BioArctic AB Registered b News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.11.20	Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020 (PR Newswire)
09.11.20	Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020 (PR Newswire)
28.10.20	BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference (PR Newswire)
28.10.20	BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference (PR Newswire)
15.10.20	BioArctic winner of the Allbright Award 2020 (PR Newswire)
15.10.20	BioArctic winner of the Allbright Award 2020 (PR Newswire)
06.10.20	Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET (PR Newswire)
06.10.20	Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET (PR Newswire)
30.07.20	Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020 (PR Newswire)
30.07.20	Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020 (PR Newswire)
22.07.20	BioArctic's Partner Eisai to Present Update on the Development of BAN2401 at Alzheimer's Association International Conference 2020 (PR Newswire)
22.07.20	BioArctic's Partner Eisai to Present Update on the Development of BAN2401 at Alzheimer's Association International Conference 2020 (PR Newswire)
14.07.20	New Global Phase 3 Program of BAN2401 Initiated in Preclinical (Asymptomatic) Alzheimer's Disease (PR Newswire)
14.07.20	New Global Phase 3 Program of BAN2401 Initiated in Preclinical (Asymptomatic) Alzheimer's Disease (PR Newswire)
01.07.20	Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET (PR Newswire)
01.07.20	Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET (PR Newswire)
29.06.20	BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease (PR Newswire)
29.06.20	BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease (PR Newswire)
26.05.20	Members of BioArctic's Board of Directors and Management Increase Their Shareholdings (PR Newswire)
26.05.20	Members of BioArctic's Board of Directors and Management Increase Their Shareholdings (PR Newswire)
07.05.20	Report from Annual General Meeting in BioArctic (publ) (PR Newswire)
07.05.20	Report from Annual General Meeting in BioArctic (publ) (PR Newswire)
22.04.20	Interim Report for the period January - March 2020 (PR Newswire)
22.04.20	Interim Report for the period January - March 2020 (PR Newswire)
15.04.20	Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET (PR Newswire)
15.04.20	Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET (PR Newswire)
03.03.20	Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401 (PR Newswire)
03.03.20	Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401 (PR Newswire)
17.12.19	BioArctic Announces Research Collaboration with Eisai Regarding BAN2401 (PR Newswire)
17.12.19	BioArctic Announces Research Collaboration with Eisai Regarding BAN2401 (PR Newswire)
10.12.19	BioArctic Strengthens its Management Team With Two Strategic Recruitments (PR Newswire)
05.12.19	BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease (PR Newswire)
05.12.19	BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease (PR Newswire)
02.12.19	BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference (PR Newswire)
02.12.19	BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference (PR Newswire)
19.11.19	BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury (PR Newswire)
19.11.19	BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury (PR Newswire)
18.07.19	BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019 (PR Newswire)
18.07.19	BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019 (PR Newswire)
15.07.19	BioArctic's Co-Founder Received AAIC Lifetime Achievement Award (PR Newswire)
15.07.19	BioArctic's Co-Founder Received AAIC Lifetime Achievement Award (PR Newswire)
11.07.19	BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019 (PR Newswire)
11.07.19	BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019 (PR Newswire)
23.05.19	BioArctic Strengthens its Blood-brain Barrier Technology Platform With World Leading Scientist Recruitment (PR Newswire)
20.05.19	BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease (PR Newswire)
20.05.19	BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease (PR Newswire)
10.05.19	BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease (PR Newswire)
10.05.19	BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease (PR Newswire)
03.04.19	BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies (PR Newswire)
03.04.19	BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	53.56	3.72 %	K V
Sonova Hldg	318.50	3.11 %	K V
Part Grp Hldg	1’381.00	2.30 %	K V
Alcon	80.90	1.81 %	K V
Lonza Grp	580.40	1.79 %	K V
Nestle	74.18	-0.75 %	K V
Geberit	500.80	-0.91 %	K V
Kuehne+Nagel Int	204.60	-1.06 %	K V
Swisscom	506.50	-1.65 %	K V
Logitech Intl	79.90	-1.75 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu BioArctic AB Registered Shs -B-

Aktien Top/Flop

Meistgelesene Nachrichten